Trial Profile
An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 03 Aug 2017 New trial record